<DOC>
	<DOCNO>NCT01960504</DOCNO>
	<brief_summary>BIOSOLVE-II prospective , international , multicenter , First Man study . The purpose study assess safety clinical performance drug elute absorbable metal scaffold ( DREAMS 2nd Generation ) .</brief_summary>
	<brief_title>First Man Study DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold ( BIOSOLVE-II )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>Subject &gt; 18 year &lt; 80 year age Written subject inform consent available prior PCI Subjects stable unstable angina pectoris document silent ischemia Subject eligible PCI Subject acceptable candidate coronary artery bypass surgery Subjects maximum two single lesion two separate coronary artery de novo lesion . Reference vessel diameter 2.23.8 mm visual estimation Target lesion length ≤ 21 mm visual estimation Target lesion stenosis visual estimation , assist QCA / IVUS : &gt; 50 % &lt; 100 % Eligible Dual Anti Platelet Therapy ( DAPT ) Pregnant breastfeed female female intend become pregnant time study Evidence myocardial infarction within 72 hour prior index procedure Subjects ≥2 fold CK level absence CK ≥3 fold CKMB level upper range limit within 24 hour prior procedure Unprotected leave main coronary artery disease Threevessel coronary artery disease time procedure Thrombus target vessel Subject currently participate another study investigational device investigational drug reach primary endpoint yet Planned interventional treatment nontarget vessel within 30 day postprocedure Subjects dialysis Planned intervention target vessel within 6month index procedure Ostial target lesion ( within 5.0 mm vessel origin ) Target lesion involve side branch &gt; 2.0 mm diameter Documented leave ventricular ejection fraction ( LVEF ) ≤ 30 % Heavily calcify lesion Target lesion locate supplied arterial venous bypass graft The target lesion require treatment device predilatation balloon prior scaffold placement ( include limit , rotational atherectomy , cut balloon etc . ) Known allergy : Acetylsalicylic Acid ( ASA ) , Heparin , Contrast medium , Sirolimus , similar drug ; scaffold material Impaired renal function ( serum creatinine &gt; 2.5 mg/dl 221 mmol/l , determine within 72 hour prior intervention ) Subject receive oral intravenous immunosuppressive therapy ( e.g. , inhaled steroid exclude ) know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , include diabetes mellitus ) Proximal distal target lesion locate stenosis might require future revascularization impede run detect diagnostic angiography Life expectancy less 1 year Planned surgery dental surgical procedure within 6 month index procedure In investigator opinion subject able comply followup requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DREAMS</keyword>
	<keyword>Drug Eluting Absorbable Metal Scaffold</keyword>
	<keyword>Scaffold</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>